02.06.2012 • NewsTevaPharmaceuticalsgenerics

Teva Chairman Buys 1 Million Shares of Drugmaker

The chairman of Teva Pharmaceutical Industries has purchased 1 million U.S.-listed shares of the world's largest generic drugmaker, the company said on Friday.

Board Chairman Phillip Frost bought the shares on Wednesday, the first day of trading on the New York Stock Exchange. Previously, the U.S.-listed shares of the Israeli company traded on Nasdaq.

Frost bought shares at prices ranging from $37.82 to $39.57, according to the company. The shares were up 0.5% at $39.38 on Friday, moving into positive territory after Teva announced Frost's purchase.

"This investment is simply a reflection of the strength of my conviction regarding Teva's bright future," Frost said in a company-released statement.

Teva, which has a market value of about $38 billion, recently installed Jeremy Levin, a former executive at Bristol-Myers Squibb, as its new chief executive.

 

 

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

Virtual Event

Downstream Purification
Bioprocess Forum

Downstream Purification

Save the Date: November 21+25, 2025
Join leading scientists, process engineers, and biomanufacturing innovators for a two-day virtual event exploring the latest breakthroughs in downstream purification.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.